Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
53882-12-5
Molecular formula
C11H6ClN3O6
Molecular weight
311.63 g/mol
Drug class
Mast-cell stabiliserantiallergic ophthalmic agent
Mechanism of action
Inhibits antigen-induced mast-cell degranulation and the release of histamine and other inflammatory mediators, in part by limiting calcium-dependent activation. It reduces ocular allergic inflammatory responses.
Indications / reported uses
Treatment of vernal keratoconjunctivitis and other allergic conjunctival disorders with authorised ophthalmic formulations.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Lodoxamide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lodoxamide Permitted Daily Exposure (PDE) report (the Lodoxamide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lodoxamide Occupational Exposure Limit (OEL) report (the Lodoxamide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.